Anti-activin A antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-11542325-B2
Application number	US-201816128831-A
Country	US
Kind code	B2
Filing date	Sep 12, 2018
Priority date	Sep 8, 2006
Publication date	Jan 3, 2023
Grant date	Jan 3, 2023

Abstract

The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.

First claim

The invention claimed is:

1. A method of attenuating cachexia in a subject, comprising administering an effective amount of a pharmaceutically acceptable composition comprising a pharmaceutically acceptable excipient and an isolated antibody or antigen binding fragment thereof, comprising:
a. a light chain variable domain (VL) comprising:
i. a light chain CDR1 sequence of SEQ ID NO:11;
ii. a light chain CDR2 sequence of SEQ ID NO:12; and
iii. a light chain CDR3 sequence of SEQ ID NO:13; and

b. a heavy chain variable domain (VH) comprising:
i. a heavy chain CDR1 sequence of SEQ ID NO:62;
ii. a heavy chain CDR2 sequence of SEQ ID NO:63; and
iii. a heavy chain CDR3 sequence of SEQ ID NO:64.

2. A method of ameliorating the loss of body weight in a subject, comprising administering an effective amount of a pharmaceutically acceptable composition comprising a pharmaceutically acceptable excipient and an isolated antibody or antigen binding fragment thereof, comprising:
a. a light chain variable domain (VL) comprising:
i. a light chain CDR1 sequence of SEQ ID NO:11;
ii. a light chain CDR2 sequence of SEQ ID NO:12; and
iii. a light chain CDR3 sequence of SEQ ID NO:13; and

b. a heavy chain variable domain (VH) comprising:
i. a heavy chain CDR1 sequence of SEQ ID NO:62;
ii. a heavy chain CDR2 sequence of SEQ ID NO:63; and
iii. a heavy chain CDR3 sequence of SEQ ID NO:64.

3. A method of ameliorating the loss of muscle mass in a subject, comprising administering an effective amount of a pharmaceutically acceptable composition comprising a pharmaceutically acceptable excipient and an isolated antibody or antigen binding fragment thereof, comprising:
a. a light chain variable domain (VL) comprising:
i. a light chain CDR1 sequence of SEQ ID NO:11;
ii. a light chain CDR2 sequence of SEQ ID NO:12; and
iii. a light chain CDR3 sequence of SEQ ID NO:13; and

b. a heavy chain variable domain (VH) comprising:
i. a heavy chain CDR1 sequence of SEQ ID NO:62;
ii. a heavy chain CDR2 sequence of SEQ ID NO:63; and
iii. a heavy chain CDR3 sequence of SEQ ID NO:64.

4. A method of ameliorating the loss of fat mass in a subject, comprising administering an effective amount of a pharmaceutically acceptable composition comprising a pharmaceutically acceptable excipient and an isolated antibody or antigen binding fragment thereof, comprising:
a. a light chain variable domain (VL) comprising:
i. a light chain CDR1 sequence of SEQ ID NO:11;
ii. a light chain CDR2 sequence of SEQ ID NO:12; and
iii. a light chain CDR3 sequence of SEQ ID NO:13; and

b. a heavy chain variable domain (VH) comprising:
i. a heavy chain CDR1 sequence of SEQ ID NO:62;
ii. a heavy chain CDR2 sequence of SEQ ID NO:63; and
iii. a heavy chain CDR3 sequence of SEQ ID NO:64.

Assignees

• Amgen Inc

Inventors

• Han Huiquan
• Chen Qing
• Kwak Keith Soo-Nyung
• Zhou Xiaolan

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• A61P5/06

  of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title